Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

Table 1 Sociodemographic characteristics and clinical features of included patients

	CD patients (n = 264)	UC patients (n = 143)
Age (yr), mean ± SD	42.9 ± 13.0	45.9 ± 13.8
Female	143 (54.2)	81 (56.6)
Educational level
Primary school	55 (26.6)	38 (38.8)
Secondary school	83 (40.1)	37 (37.7)
Higher education	69 (33.3)	23 (23.5)
Missing	57	45
Professional situation
Employed	101 (44.3)	53 (42.7)
Unemployed	61 (26.8)	33 (26.6)
Student	10 (4.4)	5 (4.0)
Retired	30 (13.2)	15 (12.1)
Other	26 (11.4)	18 (14.5)
Missing	36	19
Current smokers1	24 (9.9)	3 (2.3)
Missing	22	11
Time since IBD diagnosis (yr), median [range]	10.0 [0.5-45.0]	10.0 [0.5-31.0]
Time since moderate-to-severe diagnosis (yr), median [range]	6.0 [0.5-30.0]	5.0 [0.5-25.0]
Steroid response2
Steroid-dependent	31 (14.8)	23 (19.3)
Steroid-refractory	16 (7.7)	11 (9.2)
Not applicable (no previous use)	87 (41.6)	36 (30.3)
Unknown	75 (35.9)	49 (41.2)
Missing	55	24
Any extraintestinal manifestations	54 (37.8)	30 (38.0)
Family IBD history	33 (12.5)	15 (10.5)
Moderately to severely active disease at baseline3	118 (44.7)	36 (25.2)
UC location [Montreal classification]
E1- distal UC	--	43 (30.1)
E2- left-sided	--	26 (18.2)
E3- pancolitis	--	74 (51.7)
UC severity [Montreal classification]
S0- asymptomatic	--	57 (39.9)
S1- mild UC	--	32 (22.4)
S2- moderate UC	--	40 (28.0)
S3- severe UC	--	14 (9.8)
CD location [Montreal classification]
L1- ileal	67 (25.4)	--
L2- colonic	42 (15.9)	--
L3- ileocolonic	150 (56.8)	--
L4- upper GI tract disease	17 (6.4)	--
CD behavior [Montreal classification]
B1- Nonstricturing/nonpenetrating	58 (22.0)	--
B2- Stricturing	110 (41.7)	--
B3- Penetrating	91 (34.5)	--
Perianal disease	105 (39.8)	--
Ileal surface involved ≥ 1 m [n = 201]	38 (18.9)	--

Data are shown as n (%), except where otherwise mentioned.

¹Patients were smoking at baseline and has smoked 100 cigarettes in his/her lifetime.

²Steroid-dependent disease: patients who either (1) Were unable to reduce steroids below the equivalent of prednisolone 10 mg/d within 3 mo of starting steroids, without recurrent disease, or (2) Had a relapse within 3 mo of stopping glucocorticoids. Steroid-refractory disease: active disease despite prednisolone up to 0.75 mg/kg/d over 4 wk.

³Moderate-to-severe activity at baseline was defined as pMayo ≥ 5 (UC) and having HBI ≥ 8 or CDAI ≥ 220 (CD). IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease.